Drugs / PIVAGABINE
PIVAGABINE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00814931 | Dec 2008 | anxiety | CeNeRx BioPharma Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIVAGABINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1870796 ↗ |
| Known as | CXB722 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00814931 ↗ |
| Known as | Pivagabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1870796 ↗ |
| Modality | Small molecule | — CHEMBL1870796 ↗ |
| Route | Oral | “900 mg CXB722 oral liquid suspension twice a day for 8 days” NCT00814931 ↗ |